{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:08:25Z","timestamp":1791022105830,"version":"4.1.0"},"reference-count":53,"publisher":"American Diabetes Association","issue":"6","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,6,1]]},"abstract":"<jats:p>The effect of type 1 diabetes on bone healing and bone formation in standardized craniotomy defects created in BALB\/cByJ mice was determined. The hypothesis that advanced glycation end products (AGEs) contribute to diminished bone healing in diabetes was evaluated by assessing for the presence of the receptor for advanced glycation end products (RAGE) by immunohistochemistry in healing craniotomy defects in diabetic animals. The effect of local application of a known RAGE protein ligand, N\u03b5-(carboxymethyl)lysine (CML)\u2212mouse serum albumin (MSA), on craniotomy defect healing in normal animals was then assessed and compared to the effects of control MSA. Finally, evidence in support of the expression of RAGE mRNA and protein in osteoblastic cells was obtained. The results indicated that craniotomy defects in diabetic animals healed \u223c40% of the degree to which they healed in nondiabetic animals (P &amp;lt; 0.05). RAGE was expressed at higher levels in healing bone tissues in diabetic compared to control animals. Further studies in nondiabetic animals indicated that bone healing was reduced by 63 and 42% in lesions treated with 900 and 90 \u03bcg CML-MSA, respectively, compared to in animals treated with MSA alone (P &amp;lt; 0.05). Evidence for the expression of RAGE was obtained in mouse and rat osteoblastic cultures. These results support the contribution of AGEs to diminished bone healing in type 1 diabetes, possibly mediated by RAGE.<\/jats:p>","DOI":"10.2337\/diabetes.52.6.1502","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"1502-1510","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":185,"title":["A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes"],"prefix":"10.2337","volume":"52","author":[{"given":"Ronaldo B.","family":"Santana","sequence":"first","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermik Babakhanlou","family":"Chase","sequence":"additional","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Amar","sequence":"additional","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Biochemistry, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana T.","family":"Graves","sequence":"additional","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Biochemistry, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Trackman","sequence":"additional","affiliation":[{"name":"Boston University Goldman School of Dental Medicine, Division of Oral Biology, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Biochemistry, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031209141918700_R1","doi-asserted-by":"crossref","unstructured":"De Leeuw I, Abs R: Bone mass and bone density in maturity-type diabetics measured by the 125I photon-absorption technique. Diabetes\u200826:1130\u20131135,1977","DOI":"10.2337\/diabetes.26.12.1130"},{"key":"2022031209141918700_R2","doi-asserted-by":"crossref","unstructured":"Heath H 3rd, Lambert PW, Service FJ, Arnaud SB: Calcium homeostasis in diabetes mellitus. J Clin Endocrinol Metab\u200849:462\u2013466,1979","DOI":"10.1210\/jcem-49-3-462"},{"key":"2022031209141918700_R3","doi-asserted-by":"crossref","unstructured":"McNair P, Madsbad S, Christiansen C, Faber OK, Transbol I, Binder C: Osteopenia in insulin treated diabetes mellitus: its relation to age at onset, sex and duration of disease. Diabetologia\u200815:87\u201390,1978","DOI":"10.1007\/BF00422250"},{"key":"2022031209141918700_R4","doi-asserted-by":"crossref","unstructured":"Levin ME, Boisseau VC, Avioli LV: Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med\u2008294:241\u2013245,1976","DOI":"10.1056\/NEJM197601292940502"},{"key":"2022031209141918700_R5","doi-asserted-by":"crossref","unstructured":"Santiago JV, McAlister WH, Ratzan SK, Bussman Y, Haymond MW, Shackelford G, Weldon VV: Decreased cortical thickness and osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab\u200845:845\u2013848,1977","DOI":"10.1210\/jcem-45-4-845"},{"key":"2022031209141918700_R6","doi-asserted-by":"crossref","unstructured":"Seino Y, Ishida H: Diabetic osteopenia: pathophysiology and clinical aspects. Diabetes Metab Rev\u200811:21\u201335,1995","DOI":"10.1002\/dmr.5610110103"},{"key":"2022031209141918700_R7","doi-asserted-by":"crossref","unstructured":"Levy J, Reid I, Halstad L, Gavin JR, Avioli LV: Abnormal cell calcium concentrations in cultured bone cells obtained from femurs of obese and noninsulin-dependent diabetic rats. Calcif Tissue Int\u200844:131\u2013137,1989","DOI":"10.1007\/BF02556472"},{"key":"2022031209141918700_R8","doi-asserted-by":"crossref","unstructured":"Cozen L: Does diabetes delay fracture healing?Clin Orthop\u200882:134\u2013140,1972","DOI":"10.1097\/00003086-197201000-00017"},{"key":"2022031209141918700_R9","doi-asserted-by":"crossref","unstructured":"Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E: Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab\u200880:1194\u20131202,1995","DOI":"10.1210\/jcem.80.4.7714089"},{"key":"2022031209141918700_R10","unstructured":"Bouillon R: Diabetic bone disease: low turnover osteoporosis related to decreased IGF-I production. Verh K Acad Geneeskd Belg\u200854:365\u2013391,1992"},{"key":"2022031209141918700_R11","doi-asserted-by":"crossref","unstructured":"Aubia J, Serrano LI, Marinoso L, Hojman L, Diez A, Lloveras J, Masramon J: Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study. Calcif Tissue Int\u200842:297\u2013301,1988","DOI":"10.1007\/BF02556363"},{"key":"2022031209141918700_R12","doi-asserted-by":"crossref","unstructured":"Rico H, Hernandez ER, Cabranes JA, Gomez-Castresana F: Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics. Calcif Tissue Int\u200845:71\u201373,1989","DOI":"10.1007\/BF02561404"},{"key":"2022031209141918700_R13","doi-asserted-by":"crossref","unstructured":"Shore RM, Chesney RW, Mazess RB, Rose PG, Bargman GJ: Osteopenia in juvenile diabetes. Calcif Tissue Int\u200833:455\u2013457,1981","DOI":"10.1007\/BF02409473"},{"key":"2022031209141918700_R14","doi-asserted-by":"crossref","unstructured":"Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM: Bone loss and bone turnover in diabetes. Diabetes\u200844:775\u2013782,1995","DOI":"10.2337\/diabetes.44.7.775"},{"key":"2022031209141918700_R15","doi-asserted-by":"crossref","unstructured":"Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev\u20084:437\u2013451,1988","DOI":"10.1002\/dmr.5610040503"},{"key":"2022031209141918700_R16","doi-asserted-by":"crossref","unstructured":"Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med\u2008318:1315\u20131321,1988","DOI":"10.1056\/NEJM198805193182007"},{"key":"2022031209141918700_R17","doi-asserted-by":"crossref","unstructured":"Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J\u20086:2905\u20132914,1992","DOI":"10.1096\/fasebj.6.11.1644256"},{"key":"2022031209141918700_R18","doi-asserted-by":"crossref","unstructured":"Lalla E, Lamster IB, Feit M, Huang L, Schmidt AM: A murine model of accelerated periodontal disease in diabetes. J Periodontal Res\u200833:387\u2013399,1998","DOI":"10.1111\/j.1600-0765.1998.tb02335.x"},{"key":"2022031209141918700_R19","doi-asserted-by":"crossref","unstructured":"Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM: Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest\u2008105:1117\u20131124,2000","DOI":"10.1172\/JCI8942"},{"key":"2022031209141918700_R20","doi-asserted-by":"crossref","unstructured":"Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem\u2008274:31740\u201331749,1999","DOI":"10.1074\/jbc.274.44.31740"},{"key":"2022031209141918700_R21","doi-asserted-by":"crossref","unstructured":"Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D\u2019Agati V, Pischetsrieder M, Stern DM, Schmidt AM: Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol\u200821:905\u2013910,2001","DOI":"10.1161\/01.ATV.21.6.905"},{"key":"2022031209141918700_R22","doi-asserted-by":"crossref","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta\u20081498:99\u2013111,2000","DOI":"10.1016\/S0167-4889(00)00087-2"},{"key":"2022031209141918700_R23","unstructured":"Baynes JW, Watkins NG, Fisher CI, Hull CJ, Patrick JS, Ahmed MU, Dunn JA, Thorpe SR: The Amadori product on protein: structure and reactions. Prog Clin Biol Res\u2008304:43\u201367,1989"},{"key":"2022031209141918700_R24","doi-asserted-by":"crossref","unstructured":"Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med\u2008174:931\u2013939,1991","DOI":"10.1084\/jem.174.4.931"},{"key":"2022031209141918700_R25","doi-asserted-by":"crossref","unstructured":"Vlassara H, Brownlee M, Cerami A: Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes\u200837:456\u2013461,1988","DOI":"10.2337\/diabetes.37.4.456"},{"key":"2022031209141918700_R26","doi-asserted-by":"crossref","unstructured":"Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes\u200840:405\u2013412,1991","DOI":"10.2337\/diabetes.40.4.405"},{"key":"2022031209141918700_R27","doi-asserted-by":"crossref","unstructured":"Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors\/binding proteins. J Biol Chem\u2008269:9889\u20139897,1994","DOI":"10.1016\/S0021-9258(17)36966-1"},{"key":"2022031209141918700_R28","doi-asserted-by":"crossref","unstructured":"Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D: RAGE: a novel cellular receptor for advanced glycation end products. Diabetes\u200845 (Suppl. 3):S77\u2013S80,1996","DOI":"10.2337\/diab.45.3.S77"},{"key":"2022031209141918700_R29","doi-asserted-by":"crossref","unstructured":"Lalla E, Lamster IB, Schmidt AM: Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. Ann Periodontol\u20083:13\u201319,1998","DOI":"10.1902\/annals.1998.3.1.13"},{"key":"2022031209141918700_R30","doi-asserted-by":"crossref","unstructured":"Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF: The advanced glycation end product N epsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care\u200821:1997\u20132002,1998","DOI":"10.2337\/diacare.21.11.1997"},{"key":"2022031209141918700_R31","doi-asserted-by":"crossref","unstructured":"Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW: Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry\u200830:1205\u20131210,1991","DOI":"10.1021\/bi00219a007"},{"key":"2022031209141918700_R32","doi-asserted-by":"crossref","unstructured":"Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry\u200835:8075\u20138083,1996","DOI":"10.1021\/bi9530550"},{"key":"2022031209141918700_R33","doi-asserted-by":"crossref","unstructured":"Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry\u200834:10872\u201310878,1995","DOI":"10.1021\/bi00034a021"},{"key":"2022031209141918700_R34","doi-asserted-by":"crossref","unstructured":"Schleicher ED, Wagner E, Nerlich AG: Increased accumulation of the glycoxidation product N(epsilon)- (carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest\u200899:457\u2013468,1997","DOI":"10.1172\/JCI119180"},{"key":"2022031209141918700_R35","doi-asserted-by":"crossref","unstructured":"Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science\u2008193:415\u2013417,1976","DOI":"10.1126\/science.180605"},{"key":"2022031209141918700_R36","doi-asserted-by":"crossref","unstructured":"Marden LJ, Quigley NC, Reddi AH, Hollinger JO: Temporal changes during bone regeneration in the calvarium induced by osteogenin. Calcif Tissue Int\u200853:262\u2013268,1993","DOI":"10.1007\/BF01320912"},{"key":"2022031209141918700_R37","doi-asserted-by":"crossref","unstructured":"Marden LJ, Hollinger JO, Chaudhari A, Turek T, Schaub RG, Ron E: Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res\u200828:1127\u20131138,1994","DOI":"10.1002\/jbm.820281003"},{"key":"2022031209141918700_R38","doi-asserted-by":"crossref","unstructured":"Habeeb A: Determination of free amino groups in proteins by trinitrobenezenesilfonic acid. Anal Biochem\u200814:328\u2013336,1966","DOI":"10.1016\/0003-2697(66)90275-2"},{"key":"2022031209141918700_R39","unstructured":"Ling X, Sakashita N, Takeya M, Nagai R, Horiuchi S, Takahashi K: Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest\u200878:1591\u20131606,1998"},{"key":"2022031209141918700_R40","unstructured":"Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M: Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand)\u200844:1147\u20131157,1998"},{"key":"2022031209141918700_R41","doi-asserted-by":"crossref","unstructured":"Bellows CG, Aubin JE, Heersche JN, Antosz ME: Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int\u200838:143\u2013154,1986","DOI":"10.1007\/BF02556874"},{"key":"2022031209141918700_R42","doi-asserted-by":"crossref","unstructured":"Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med\u20084:1025\u20131031,1998","DOI":"10.1038\/2012"},{"key":"2022031209141918700_R43","unstructured":"Leiter EH, Prochazka M, Coleman DL: The non-obese diabetic (NOD) mouse. Am J Pathol\u2008128:380\u2013383,1987"},{"key":"2022031209141918700_R44","doi-asserted-by":"crossref","unstructured":"Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N: Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res\u200811:931\u2013937,1996","DOI":"10.1002\/jbmr.5650110709"},{"key":"2022031209141918700_R45","doi-asserted-by":"crossref","unstructured":"Katayama Y, Celic S, Nagata N, Martin TJ, Findlay DM: Nonenzymatic glycation of type I collagen modifies interaction with UMR 201\u201310B preosteoblastic cells. Bone\u200821:237\u2013242,1997","DOI":"10.1016\/S8756-3282(97)00128-2"},{"key":"2022031209141918700_R46","doi-asserted-by":"crossref","unstructured":"Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T: Advanced glycation endproducts stimulate Interleukin-6 production by human bone derived cells. J Bone Miner Res\u200812:439\u2013446,1997","DOI":"10.1359\/jbmr.1997.12.3.439"},{"key":"2022031209141918700_R47","doi-asserted-by":"crossref","unstructured":"Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem\u2008267:14998\u201315004,1992","DOI":"10.1016\/S0021-9258(18)42138-2"},{"key":"2022031209141918700_R48","doi-asserted-by":"crossref","unstructured":"Goodman WG, Hori MT: Diminished bone formation in experimental diabetes: relationship to osteoid maturation and mineralization. Diabetes\u200833:825\u2013831,1984","DOI":"10.2337\/diabetes.33.9.825"},{"key":"2022031209141918700_R49","doi-asserted-by":"crossref","unstructured":"Wu K, Schubeck KE, Frost HM, Villanueva A: Haversian bone formation rates determined by a new method in a mastodon, and in human diabetes mellitus and osteoporosis. Calcif Tissue Res\u20086:204\u2013219,1970","DOI":"10.1007\/BF02196201"},{"key":"2022031209141918700_R50","doi-asserted-by":"crossref","unstructured":"McCarthy AD, Etcheverry SB, Cortizo AM: Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol\u200836:45\u201352,1999","DOI":"10.1007\/s005920050144"},{"key":"2022031209141918700_R51","doi-asserted-by":"crossref","unstructured":"Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A\u200889:12043\u201312047,1992","DOI":"10.1073\/pnas.89.24.12043"},{"key":"2022031209141918700_R52","doi-asserted-by":"crossref","unstructured":"Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A\u200891:11704\u201311708,1994","DOI":"10.1073\/pnas.91.24.11704"},{"key":"2022031209141918700_R53","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S: Role of advanced glycation end products in a dynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis\u200838:S161\u2013S164,2001","DOI":"10.1053\/ajkd.2001.27428"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/52\/6\/1502\/375045\/db0603001502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/52\/6\/1502\/375045\/db0603001502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:18:08Z","timestamp":1667405888000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/52\/6\/1502\/14041\/A-Role-for-Advanced-Glycation-End-Products-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,1]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.52.6.1502","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,1]]}}}